Stage-Associated Microglial Subpopulations and Dynamics in Vascular Pathogenesis of Oxygen-Induced Retinopathy

Abstract

Retinal neovascularisation (RNV) is manifested in various retinal pathological conditions, often leading to irreversible blindness. The oxygen-induced retinopathy (OIR) mouse model proves to be a useful tool for understanding RNV pathogenesis. In this model, retinal vascular phenotype undergoes two distinct stages: neovascular formation, followed by spontaneous regression. While microglial functions in the neovascular formation stage have been extensively studied, their behaviors and roles during regression remain unclear. In this study, we characterise the spatiotemporal dynamics and molecular heterogeneity of retinal microglia across both stages. During RNV formation, microglia exhibit an outer-to-inner and central-to-midperipheral migration pattern, whereas a reversed migration trend is observed during regression. We confirm a highly glycolytic microglia (HGM) subpopulation during RNV formation and demonstrate its pro-angiogenic role by targeting a highly expressed pyruvate kinase M2 (Pkm2), a crucial enzyme for glycolysis. Importantly, we find that microglia exhibit enhanced phagocytic activity during regression, constituting a distinct phagocytosis-associated microglia (PAM) subtype, expressing mannose receptor C-type 1 (Mrc1/CD206). Altogether, our findings reveal stage-specific microglial functional dynamics, providing novel insights into RNV pathogenesis and intervention.

Keywords

microglia / oxygen-induced retinopathy / phagocytosis / Pkm2 / retinal neovascularisation

References

[1] A. Uemura, M. Fruttiger, P. A. D'Amore, et al., “VEGFR1 Signaling in Retinal Angiogenesis and Microinflammation,” Progress in Retinal and Eye Research 84 (2021): 100954.

[2] Y. Usui, P. D. Westenskow, S. Murinello, et al., “Angiogenesis and Eye Disease,” Annual Review of Vision Science 1 (2015): 155–184.

[3] A. Usui-Ouchi and M. Friedlander, “Anti-VEGF Therapy: Higher Potency and Long-Lasting Antagonism Are Not Necessarily Better,” Journal of Clinical Investigation 129 (2019): 3032–3034.

[4] T. Q. Kwong and M. Mohamed, “Anti-Vascular Endothelial Growth Factor Therapies in Ophthalmology: Current Use, Controversies and the Future,” British Journal of Clinical Pharmacology 78 (2014): 699–706.

[5] S. E. Liyanage, A. Fantin, P. Villacampa, et al., “Myeloid-Derived Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor Are Dispensable for Ocular Neovascularization—Brief Report,” Arteriosclerosis, Thrombosis, and Vascular Biology 36 (2016): 19–24.

[6] A. Hu, M. H. H. Schmidt, and N. Heinig, “Microglia in Retinal Angiogenesis and Diabetic Retinopathy,” Angiogenesis 27 (2024): 311–331.

[7] F. Li, D. Jiang, and M. A. Samuel, “Microglia in the Developing Retina,” Neural Development 14 (2019): 12.

[8] W. Xu, Z. Hu, Y. Lv, et al., “Microglial Density Determines the Appearance of Pathological Neovascular Tufts in Oxygen-Induced Retinopathy,” Cell and Tissue Research 374 (2018): 25–38.

[9] C. Brockmann, S. Dege, S. Crespo-Garcia, et al., “Spatial Distribution of CD115(+) and CD11b(+) Cells and Their Temporal Activation During Oxygen-Induced Retinopathy in Mice,” Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie 256 (2018): 313–323.

[10] A. M. Jurga, M. Paleczna, and K. Z. Kuter, “Overview of General and Discriminating Markers of Differential Microglia Phenotypes,” Frontiers in Cellular Neuroscience 14 (2020): 198.

[11] Y. Tang and W. Le, “Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases,” Molecular Neurobiology 53 (2016): 1181–1194.

[12] K. Borst, M. Schwabenland, and M. Prinz, “Microglia Metabolism in Health and Disease,” Neurochemistry International 130 (2019): 104331.

[13] G. Soto-Heredero, M. M. de Gómez Las Heras, E. Gabandé-Rodríguez, J. Oller, and M. Mittelbrunn, “Glycolysis - a Key Player in the Inflammatory Response,” FEBS Journal 287 (2020): 3350–3369.

[14] Y. L. Tan, Y. Yuan, and L. Tian, “Microglial Regional Heterogeneity and Its Role in the Brain,” Molecular Psychiatry 25 (2020): 351–367.

[15] H. Keren-Shaul, A. Spinrad, A. Weiner, et al., “A Unique Microglia Type Associated With Restricting Development of Alzheimer's Disease,” Cell 169 (2017): 1276–1290.e1217.

[16] J. Zhong, G. Tang, J. Zhu, et al., “Single-Cell Brain Atlas of Parkinson's Disease Mouse Model,” Journal of Genetics and Genomics 48 (2021): 277–288.

[17] T. R. Hammond, C. Dufort, L. Dissing-Olesen, et al., “Single-Cell RNA Sequencing of Microglia Throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes,” Immunity 50 (2019): 253–271.e256.

[18] E. Friebel, K. Kapolou, S. Unger, et al., “Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes,” Cell 181 (2020): 1626–1642.e1620.

[19] C. He, Y. Liu, Z. Huang, et al., “A Specific RIP3(+) Subpopulation of Microglia Promotes Retinopathy Through a Hypoxia-Triggered Necroptotic Mechanism,” Proceedings of the National Academy of Sciences of the United States of America 118 (2021): e2023290118.

[20] Q. Luo, Z. Jiang, J. Jiang, et al., “Tsp-1(+) Microglia Attenuate Retinal Neovascularization by Maintaining the Expression of Smad3 in Endothelial Cells Through Exosomes With Decreased miR-27a-5p,” Theranostics 13 (2023): 3689–3706.

[21] Z. Liu, H. Shi, J. Xu, et al., “Single-Cell Transcriptome Analyses Reveal Microglia Types Associated With Proliferative Retinopathy,” JCI Insight 7 (2022): e160940.

[22] K. M. Connor, N. M. Krah, R. J. Dennison, et al., “Quantification of Oxygen-Induced Retinopathy in the Mouse: A Model of Vessel Loss, Vessel Regrowth and Pathological Angiogenesis,” Nature Protocols 4 (2009): 1565–1573.

[23] A. M. Santos, R. Calvente, M. Tassi, et al., “Embryonic and Postnatal Development of Microglial Cells in the Mouse Retina,” Journal of Comparative Neurology 506 (2008): 224–239.

[24] H. Zhong, H. Yu, J. Sun, et al., “Isolation of Microglia From Retinas of Chronic Ocular Hypertensive Rats,” Open Life Sciences 16 (2021): 992–1001.

[25] Y. Ma and T. Li, “Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model,” Journal of Visualized Experiments 170 (2021): e62410.

[26] T. Wu, E. Hu, S. Xu, et al., “clusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data,” Innovation 2 (2021): 100141.

[27] E. G. O'Koren, C. Yu, M. Klingeborn, et al., “Microglial Function Is Distinct in Different Anatomical Locations During Retinal Homeostasis and Degeneration,” Immunity 50 (2019): 723–737.e727.

[28] C. Yang, L. Wang, Y. Liu, et al., “Thermal Proteome Profiling Reveals Meltome Upon NLRP3 Inflammasome Activation,” Molecular & Cellular Proteomics 24 (2025): 100972.

[29] H. Nakanishi, “Microglial Functions and Proteases,” Molecular Neurobiology 27 (2003): 163–176.

[30] K. Zhai, N. Jiang, J. F. Wen, et al., “Overexpression of TWF1 Promotes Lung Adenocarcinoma Progression and Is Associated With Poor Prognosis in Cancer Patients Through the MMP1 Signaling Pathway,” Journal of Thoracic Disease 15 (2023): 2644–2658.

[31] M. Yamaguchi, S. Nakao, M. Arima, et al., “Heterotypic Macrophages/Microglia Differentially Contribute to Retinal Ischaemia and Neovascularisation,” Diabetologia 67 (2024): 2329–2345.

[32] Z. Y. Zhou, T. F. Chang, Z. B. Lin, et al., “Microglial Galectin3 Enhances Endothelial Metabolism and Promotes Pathological Angiogenesis via Notch Inhibition by Competitively Binding to Jag1,” Cell Death & Disease 14 (2023): 380.

[33] K. Zou, X. Li, B. Ren, F. Cheng, J. Ye, and Z. Ou, “Single-Cell Analysis Identifies MKI67(+) Microglia as Drivers of Neovascularization in Proliferative Diabetic Retinopathy,” Journal of Translational Medicine 23 (2025): 310.

[34] R. Orihuela, C. A. McPherson, and G. J. Harry, “Microglial M1/M2 Polarization and Metabolic States,” British Journal of Pharmacology 173 (2016): 649–665.

[35] Z. Liu, J. Xu, Q. Ma, et al., “Glycolysis Links Reciprocal Activation of Myeloid Cells and Endothelial Cells in the Retinal Angiogenic Niche,” Science Translational Medicine 12 (2020): eaay1371.

[36] O. J. Mezu-Ndubuisi, T. Adams, L. K. Taylor, A. Nwaba, and J. Eickhoff, “Simultaneous Assessment of Aberrant Retinal Vascularization, Thickness, and Function in an In Vivo Mouse Oxygen-Induced Retinopathy Model,” Eye (London, England) 33 (2019): 363–373.

[37] M. L. Bennett, F. C. Bennett, S. A. Liddelow, et al., “New Tools for Studying Microglia in the Mouse and Human CNS,” Proceedings of the National Academy of Sciences of the United States of America 113 (2016): E1738–E1746.

[38] A. Stahl, J. Chen, P. Sapieha, et al., “Postnatal Weight Gain Modifies Severity and Functional Outcome of Oxygen-Induced Proliferative Retinopathy,” American Journal of Pathology 177 (2010): 2715–2723.

[39] S. Selvam, T. Kumar, and M. Fruttiger, “Retinal Vasculature Development in Health and Disease,” Progress in Retinal and Eye Research 63 (2018): 1–19.

[40] V. Bergen, M. Lange, S. Peidli, F. A. Wolf, and F. J. Theis, “Generalizing RNA Velocity to Transient Cell States Through Dynamical Modeling,” Nature Biotechnology 38 (2020): 1408–1414.

Rights & permissions

2026 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.